completion facility BLA, the manufacturing will an rolling in nearing III our forward Earlier the facility the Omidubicel, of the important second owned to in allowed our and commercial we on us planned completion move year. FDA’s I readiness are to quarter compared acknowledgement This our BLA this comparability with this Thank year, our in Israel Gamida track launch remaining used for comment of the advancements for year, you, is modules in we support analytical the production the submission with which first Israel, now as the of Cell we Phase from Omidubicel. In for our module BLA. to our initiated CMC milestone quarter on Ronit. study. facility rolling reached for of this of and with the completion
submission operations and progressing functional in module module quality cross and second are quarter. regulatory for team CMC the well that BLA including the preparation completing in R&D the on Our in Israel,
preparing preparing readiness. the an BLA from are perspective, also submission for not for operations launch We only but
modular the Our approval to ability will Omidubicel. add demand from facility in have upon grows FDA and of we additional Omidubicel, as Israel cores is
chain of We from team chain also a identity patients patient unmet team are our ensure the approval. confident address supply commercial but manufacturing of launch only for a positive facility, need reliability, we ensure from and to the to the readiness, standpoint. demand process experience. production, support a transplant center our may that working launch not positive our FDA Transitioning requirements is diligently Omidubicel custody to upon for recognizes Gamida chain could The and
on patients to access Omidubicel. to FDA our focused upon are have ensure launch approval could that readiness We
key two For deemed chance may procedure are their for stem cell transplant, patients opportunities patients allergenic FDA potential address Omidubicel eligible approval. with for that an hematologic are upon for be malignancies best cure. a the that may There
first the cell potentially increasing outcomes year. allogeneic States being second age other on XX as to transplant patients and access transplant of undergo stem who the X,XXX The malignancies improving United based are with In above approximately potentially or compared feedback each hematologic the an sources donor
we is to patients improving on of one opportunities market outcomes, ability two the years, the patients insights For see extensive of and the of within Transplanters the the The identification. provide Omidubicel number clinical have with other for ability outcomes are based strength Omidubicel with of This the sources. donor approximately data, transplant to majority States cells consistent patient that and puts the to take potentially two United find at due unfortunately important provide risk eligible conducted patient still over hematologic the their relapse. up least on donors to and three approximately experience to month stem patients clear. the at donor an research donor. and last an our donor. unrelated cell improve pre-defined unrelated ages XX months their and allogeneic each receiving who year who This cannot there for for in are graft appropriate align from patient average, Unfortunately, and X,XXX could are malignancies, are are for with the timing deemed to potentially but
regards disparity in for In potentially cell U.S. access transplants. there in increasing racial to the stem access terms unfortunately, to allogeneic patients, is of
the and non-Caucasian to access in are match not do database. you likelihood you public finding have a If very a family member have low donor, of a
a who III Omidubicel a demonstrated patients American in XX% patients ability non-Caucasian. African in our have racially finding criteria, and has to less approximately in we Phase matching highlighted match example, diverse racial of study And a to patients of stringent increases project our our XX% use were of a available were ethnically Omidubicel in of may For potentially racial among are and eligible match. study patients and recently chance less than associated undergoing population the modeling Presentation transplant and model potentially a Poster registry with population with minorities. on the TCT, at ethnic greater higher improvements disparities. outcomes data proportions overall potential we patients the in Omidubicel impact improved being and leveraged In study,
improving together the and we approval, peak these of addressable opportunities both that Omidubicel on result increasing access to XX% outcomes anticipate may market feedback Taken we once approximately based reach pending FDA transplant two or market XX% share. in combined capturing
would So upon FDA allogeneic stem the to each centers are Omidubicel. X,XXX cell transplant treated in equate approval, year approximately that reaching U.S., in In transplants centers transplant this to the U.S. extremely alone perform patients the X,XXX regards to concentrated. with
centers approximately for optimized those approximately that by those are For transplants, XXX U.S., transplant the reference in allowing transplants, allogeneic perform initially cell targeting stem approach of of to commercialization centers. XX% an centers XX the conduct there
and engaging Another understand underway to-date. of hear the and ensure Payer potential approval. Omidubicel the data with to Omidubicel, published feedback health have the launch payers including they national data encouraging payers we proposition that value important of regional clinical value continue aspect economic upon of conversations on is of with FDA the key and strength our are the to overall we consistent
We are and the approach with they FDA Omidubicel reimbursement taking upon their feedback on also by both anticipate encouraged approval. coverage
provide hear are the now are continuing results. on review Omidubicel. Shai. all feedback to to extremely I over potential look call financial by We and commercial will encouraged driven our We the excited stakeholders to to preparations. continue and Shai turn forward to of to positive our across updates
